GEROPHARM at BIOCHINA 2025 biotech convention
GEROPHARM participated in the China’s largest, 10th biomedicinal convention, BIOCHINA 2025, held in Suzhou. This large-scale event brought together leading biotech and pharma experts from China and other countries. The convention participants discussed a wide range of topical subjects, including development and clinical studies in the area of cell and gene therapy, monoclonal antibodies, vaccines, synthetic medicines, peptide-based medicinal products, and nucleic acids.
Within the Convention, a Russia and China Forum took place, where Svetlana Zakirova, Business Development Director of GEROPHARM spoke as well. At the panel session dedicated to business development and potential licensing cooperation between China and Russia concerning biologics, she stressed out the importance to develop partnership between Russia and China in the spheres of public health, pharmaceutical and medicinal industries. “Today, Russian companies are interested in transfer of advanced technologies from China, including localisation of full-cycle production facilities at the territory of Russia, and Chinese business representatives are eager to respond to our requests and develop offers for joint investment project preparation,” Svetlana Zakirova summed it up.
Anatoly Borodin, Head of Strategic Development Unit of GEROPHARM, shared his impressions, “Recently, China has done a great leap forward in numbers and quality in the area of medicinal product development, and BioChina makes it evident. Owing to such events, we can track new trends in research and development that will result in new products in 3–5 years, and build trusting relations with the Chinese partners to make Chinese innovations accessible to Russian patients in the future.”
BIOCHINA 2025 Convention and Exhibition occupied five pavilions with a total area exceeding 50 thousand square metres. Over 10 thousand delegates from all over the world attended the event. The exhibitors presented a wide range of products and services, including pharmaceutical equipment, laboratory tools, engineering solutions, raw materials, reagents and consumables, and demonstrated maturity and innovative potential of the industry.
